Matthew R. Smith, MD, PhD - Combined Systemic Therapy to Combat Metastatic Hormone-Sensitive Prostate Cancer

episode

CME in Minutes: Education in Oncology & Hematology not yet transcribed

▲ 0

Transcript

This episode hasn't been transcribed yet Upvotes decide what gets transcribed next — 0 so far. Sign in to upvote

Related

recent transcribed audio

NPR News: 09-22-2026 7PM EDT 4 min · 22 Sep 2026 · NPR News Now

Garry and Tim - Full Show - Wednesday September 23 (23.09.26) 1h 53m · 22 Sep 2026 · SEN Breakfast

H4 N2K, Shehan Jeyarajah, The Kicker 45 min · 22 Sep 2026 · The Program

US-Iran Talks on Sidelines of UN Summit, Chipmakers Rally, More 7 min · 22 Sep 2026 · Bloomberg News Now

7PM ET 09/22/2026 Newscast 3 min · 22 Sep 2026 · Fox News Hourly Update

Dentists Are Making Millions From This Lie - Dr. Ellie Phillips EXPOSES the dental industry 1h 5m · 22 Sep 2026 · Redacted News

Report any issue

Source

Recorded22 Sep 2023

Publisherc.answersincme.com ↗

Handlerec:766066

Show notes

Please visit answersincme.com/WGA860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in oncology discusses the role of triplet therapy for patients with metastatic hormone-sensitive prostate cancer. Upon completion of this activity, participants should be better able to: Discuss recommended, evidence-based triplet therapies for patients with metastatic hormone-sensitive prostate cancer (mHSPC); Recognize patient and disease factors that can guide the selection of triplet treatment strategies for mHSPC; and Explain how to minimize adverse events for patients being treated with triplet therapy for mHSPC.

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Sign in